There are two classes of EGFR antagonists that are used in clinical practice for non-small cell lung cancer at this time: anti-EGFR monoclonal antibody (cetuximab), and small-molecule EGFR tyrosine kinase inhibitors (TKIs) (gefitinib and erlotinib). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.